FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory...

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)

Medical Device Quality Management System Regulation Risk Management

January 10, 2025 Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) Meeting

VIRTUAL PRESS CONFERENCE: FDA’s Proposed Rule on Reducing Nicotine Levels – 1/15/2025

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S08 – Symposium Wrap-up and...

Medical Device Quality Management System Regulation Design and Development

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

¿Por qué existe la FDA?

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S04 - (PV): International...

FDA Direct: FDA Awards Six National Priority Vouchers

GCP & Pharmacovigilance Compliance Symposium | D3S03-1 - (BE): Clinical Study Conduct

What Does FDA Regulate?

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S07 – Q&A Discussion Panel